Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Inhaled Ribavirin (CCI15106) in Healthy and COPD Participants
NCT03235726Phase 1Completed
- Sponsor
- GSK
- Start
- Jul 2017
- Primary completion
- Jun 2018
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ribavirin in chronic obstructive pulmonary disease (COPD) (9 cohorts), sponsored by GSK. Primary endpoints: Number of Participants With Non-serious Adverse Events (NSAEs) and Serious Adverse Events (SAEs) up to 51 days, Number of Participants With Hematology Values of Potential Clinical Importance (PCI) up to 51 days and 18 more. Started Jul 2017; status: completed.
02
Drugs
ribavirin
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03235726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03235726.